The below ASCO abstracts demonstrate how the Syapse platform powers research efforts through a differentiated approach to real-world data utilizing longitudinal multi-source capture of the clinical and genomic steps within the patient journey.
If you have credentials for ASCO20 and would like to visit our virtual exhibit it can be found here
Through its research collaboration agreement with the FDA, Syapse has pursued addressing questions in the context of both published clinical trial data and real-world data with assessment of alignment and/or complementarity of these two realms; this is exemplified by two ASCO abstracts reporting on survivorship of patients with gradations of PD-L1 expression treated with immune check-point inhibitors.
Syapse serves as a convener of and contributor to collaborative research using real-world data, working with members of the Syapse Learning Health Network (LHN) to answer meaningful clinical questions, as exemplified by work with Advocate Aurora Health regarding molecularindicators of hyper-progression in patients receiving immune check point inhibitor therapy.
Syapse participated in a national effort facilitated by the Friends of Cancer Research (FOCR) to explore the ability to aggregate findings across real-world data sources. This work is represented by two ASCO abstracts reporting on outcomes and comorbidities of real-world cohorts treated with immune check-point inhibitors and/or chemotherapy.